Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT2 | P31751 | 8/20 | 0.70 |
| ▸ | PRKACA | P17612 | 4/20 | 0.62 |
| ▸ | PRKACG | P22612 | 4/20 | 0.62 |
| ▸ | PRKACB | P22694 | 4/20 | 0.62 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.60 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.60 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.60 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.59 |
| ▸ | AKT1 | P31749 | 2/20 | 0.54 |
| ▸ | NEK2 | P51955 | 1/20 | 0.52 |
| ▸ | CDC7 | O00311 | 2/20 | 0.51 |
| ▸ | DBF4 | Q9UBU7 | 2/20 | 0.51 |
| ▸ | EGFR | P00533 | 1/20 | 0.51 |
| ▸ | CSF1R | P07333 | 1/20 | 0.51 |
| ▸ | NT5C2 | P49902 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28753405 | 0.81 | AKT2 (0.60) | AKT2PRKACAPRKACGPRKACBMAPK14 | |
| SCHEMBL27628959 | 0.81 | AKT2 (0.60) | AKT2PRKACAPRKACGPRKACBMAPK14 | |
| SCHEMBL18486287 | 0.80 | TOP2A (0.62) | AKT2PRKACAPRKACGPRKACBNEK2 | |
| SCHEMBL19288719 | 0.79 | AKT2 (0.54) | AKT2PRKACAPRKACGPRKACBAKT1 | |
| SCHEMBL1900510 | 0.78 | NEK2 (0.58) | AKT2PRKACAPRKACGPRKACBMAPK14 | |
| SCHEMBL3492637 | 0.77 | AKT2 (0.50) | AKT2PRKACAPRKACGPRKACBMAPK14 | |
| SCHEMBL30862619 | 0.76 | PI4KA (0.55) | AKT2PRKACAPRKACGPRKACB | |
| SCHEMBL28765140 | 0.76 | AKT2 (0.52) | AKT2PRKACAPRKACGPRKACBMAPK14 | |
| SCHEMBL7035594 | 0.76 | PI4KA (0.50) | AKT2PRKACAPRKACGPRKACBCDC7 | |
| SCHEMBL24500180 | 0.75 | ADORA3 (1.00) | ADORA3ADORA2AADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 143 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4363043-B1 | COMPOSITIONS FOR USE IN METHODS FOR INCREASING CANCER CELL SENSITIVITY TO ALTERNATING ELECTRIC FIELDS | NOVOCURE GMBH (CH) | 2026-04-22 | — | — | EP | claimed |
| CN-118931997-A | Method for synthesizing adenosine and/or uridine by three-enzyme cascade catalysis | 上海飞腾医药科技有限公司 | 2024-11-12 | — | — | CN | claimed |
| US-20240316012-A1 | METHODS FOR TREATING LYMPHOMA | NORTHWESTERN UNIVERSITY (US) | 2024-09-26 | — | — | US | claimed |
| US-20240219403-A1 | METHODS FOR INHIBITING KRAS ONCOPROTEIN THROUGH ENHANCED GTPASE ACTIVITY | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2024-07-04 | — | — | US | claimed |
| WO-2022217073-A1 | METHODS FOR INHIBITING KRAS ONCOPROTEIN THROUGH ENHANCED GTPASE ACTIVITY | MEMORIAL SLOAN-KETTERING CANCER CENTER (US) | 2022-10-13 | — | — | WO | claimed |
| WO-2022093770-A1 | COMBINATION THERAPY WITH PI3K-AKT-MTOR INHIBITORS AND FERROPTOSIS INDUCING AGENTS TO TREAT CANCER | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2022-05-05 | — | — | WO | claimed |
| CN-102293119-A | Processing method for increasing benefits of banana ears | — | 2011-12-28 | — | — | CN | claimed |
| US-5817799-A | 2'-Fluorofuranosyl derivatives and methods for preparing 2'-fluoropyrimidine and 2'-fluoropurine nucleosides | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1998-10-06 | — | — | US | claimed |
| EP-0540686-B1 | 2'-FLUOROFURANOSYL DERIVATIVES AND NOVEL METHOD OF PREPARING 2'-FLUOROPYRIMIDINE AND 2'-FLUOROPURINE NUCLEOSIDES | US COMMERCE (US) | 1995-08-30 | — | — | EP | claimed |
| EP-0540686-A4 | 2'-FLUOROFURANOSYL DERIVATIVES AND NOVEL METHOD OF PREPARING 2'-FLUOROPYRIMIDINE AND 2'-FLUOROPURINE NUCLEOSIDES | US COMMERCE (US) | 1993-05-26 | — | — | EP | claimed |
| EP-0540686-A1 | 2'-FLUOROFURANOSYL DERIVATIVES AND NOVEL METHOD OF PREPARING 2'-FLUOROPYRIMIDINE AND 2'-FLUOROPURINE NUCLEOSIDES. | US COMMERCE (US) | 1993-05-12 | — | — | EP | claimed |
| WO-1992001700-A1 | 2'-FLUOROFURANOSYL DERIVATIVES AND NOVEL METHOD OF PREPARING 2'-FLUOROPYRIMIDINE AND 2'-FLUOROPURINE NUCLEOSIDES | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, U.S. DEPARTMENT OF COMMERCE (US) | 1992-02-06 | — | — | WO | claimed |
| CN-121991068-A | 6-Phenyl-purine derivative, preparation method and medical application thereof | 南通大学 | 2026-05-08 | — | — | CN | disclosed |
| CN-121991068-A | 6-Phenyl-purine derivative, preparation method and medical application thereof | 南通大学 | 2026-05-08 | — | — | CN | disclosed |
| EP-4729067-A2 | ELECTRODE ASSEMBLY FOR APPLYING TUMOR TREATING FIELDS WITH A SHEET OF ANISOTROPIC MATERIAL | Novocure GmbH (CH) | 2026-04-22 | — | — | EP | disclosed |
| US-12415844-B2 | BCMA specific VCAR compositions and methods for use | POSEIDA THERAPEUTICS, INC. (US) | 2025-09-16 | — | — | US | disclosed |
| WO-2000069876-A1 | 4'-C-ETHYNYL PYRIMIDINE NUCLEOSIDES | YAMASA CORPORATION (JP) | 2000-11-23 | — | — | WO | disclosed |
| WO-2000069877-A1 | 4'-C-ETHYNYL PURINE NUCLEOSIDES | YAMASA CORPORATION (JP) | 2000-11-23 | — | — | WO | disclosed |
| US-6103707-A | TREATMENT OF HERPES SIMPLEX VIRUS 1 (HSV-1), HERPES SIMPLEX VIRUS 2 (HSV-2), HUMAN CYTOMEGALOVIRUS (HCMV) AND VARICELLA-ZOSTER VIRUS | YAMASA CORPORATION (JP) | 2000-08-15 | — | — | US | disclosed |
| EP-0839813-A1 | 9-(2-DEOXY-2-FLUORO-4-THIO-BETA-D-ARABINOFURANOSYL)PURINE DERIVATIVES | YAMASA CORPORATION (JP) | 1998-05-06 | — | — | EP | disclosed |